Posts by: Leonor Mateus Ferreira

Leonor Mateus Ferreira

Leonor Mateus Ferreira is an emerging journalist with a Batchelor's degree in Communication and post-graduate degree in Multiplatform Journalism. She is particularly interested in politics and current affairs, and is currently studying for a masters degree in economics and public policies.

November 20, 2015November 20, 2015

Autoimmune Research Laboratory at UCSF to Be Established After Receiving Parker Foundation Gift

News

A new research laboratory will be established at the UC San Francisco Diabetes Center thanks to a $10 million gift granted by The Parker Foundation. The facility will be focused ... Read more

June 3, 2015June 3, 2015

Roche to Present Latest Data on RA Therapy at EULAR 2015

News, rheumatoid arthritis

Roche has been invited to participate in the European League Against Rheumatism Annual Congress (EULAR 2015) and present its latest data regarding treatments for rheumatoid arthritis and other severe autoimmune diseases. ... Read more

February 23, 2015February 23, 2015

International Study to Focus on Inflammation’s Role in Arthritis, Heart Failure

News, rheumatoid arthritis

In order to understand the role of inflammation in both rheumatoid arthritis and heart failure, an international team of medical researchers is beginning a novel investigation based at the Canadian Dalhousie ... Read more

February 20, 2015February 20, 2015

Novel Nuclear Medicine Product Can Diagnose and Monitor Rheumatoid Arthritis

News

A new technology based on nuclear medicine has been developed and presented by the NCBJ POLATOM Radioisotope Centre located in Warsaw, Poland to be used in the diagnosis of inflammatory conditions. The ... Read more

February 16, 2015February 16, 2015

Amgen Anticipates FDA Approval of Adalimumab Biosimilar For RA Based on Positive Phase III Results

News, rheumatoid arthritis

Amgen has announced encouraging results from a Phase 3 study designed to assess its biosimilar candidate ABP 501 in patients who suffer from moderate to severe rheumatoid arthritis. The research was designed to evaluate ... Read more

February 13, 2015February 13, 2015

ANI Pharmaceuticals Launches Etodolac Capsules for Rheumatoid and Osteoarthritis

News, rheumatoid arthritis

Emerging generic pharmaceutical company, ANI Pharmaceuticals, Inc. is going to launch a new drug for the management of the symptoms and signs of both rheumatoid arthritis and osteoarthritis, as well as acute ... Read more

February 6, 2015February 6, 2015

Neovacs Adds New Members to Scientific Advisory Board

News

Biotechnology company, Neovacs recently added new members to its Scientific Advisory Board (SAB), in order to assist the company in their mission to provide active immunotherapies to treat autoimmune diseases, such as ... Read more

February 2, 2015February 2, 2015

Enbrel Biosimilar by Samsung Bioepis to be Reviewed by EMA

News

Enbrel (etanercept) biosimilar candidate, SB4, developed by Samsung Bioepis Co., Ltd. for patients with moderate-to-severe rheumatoid arthritis, recently received validation and has been accepted for review by the European Medicines Agency ... Read more

January 28, 2015January 28, 2015

Immune Therapeutics Signs With KRS Global Biotech on Low Dose Naltrexone

News

Immune Therapeutics, Inc. has signed an agreement with KRS Global Biotechnology, Inc., to collaborate on compounding, packaging and distributing the drug naltrexone, which is indicated for the treatment of several diseases, ... Read more

January 19, 2015January 20, 2015

Biosimilars to Raise Rheumatoid Arthritis Therapies’ Value Until 2023

News

The market for the treatment of rheumatoid arthritis (RA) will continue to experience a steady growth internationally, from a $15.6 billion value in 2013 to $19.3 billion come 2023, which matches ... Read more

Pin It on Pinterest